Show simple item record

dc.contributor.authorHolland, DJ
dc.contributor.authorMarwick, TH
dc.contributor.authorHaluska, BA
dc.contributor.authorLeano, R
dc.contributor.authorHordern, MD
dc.contributor.authorHare, JL
dc.contributor.authorFang, ZY
dc.contributor.authorPrins, JB
dc.contributor.authorStanton, T
dc.date.accessioned2022-01-25T09:57:12Z
dc.date.available2022-01-25T09:57:12Z
dc.date.issued2015
dc.identifier.issn1355-6037
dc.identifier.doi10.1136/heartjnl-2014-307391
dc.identifier.urihttp://hdl.handle.net/10072/411736
dc.description.abstractObjective: New imaging techniques have permitted the detection of subclinical LV dysfunction (LVD) in up to half of patients with type 2 diabetes mellitus (DM) with a normal EF. However, the connection between early LVD and prognosis is unclear. This study aimed to define the long-term outcome of LVD associated with type 2 DM. Methods: In this prospective cohort study, 230 asymptomatic patients with type 2 DM underwent measurement of global longitudinal 2D strain (GLS) for detection of LVD and were followed for up to 10 years. All subjects had normal EF (≥50%) and no evidence of coronary artery disease at recruitment. Outcome data were obtained through centralised state-wide death and hospital admission registries. The primary endpoint was all-cause mortality and hospitalisation. Results: On study entry, almost half (45%) of the cohort had evidence of LVD as detected by GLS. Over a median follow-up of 7.4±2.6 years (range 0.6-9.7 years), 68 patients (30%) met the primary endpoint (LVD: 37%; normal LV function: 24%). GLS was independently associated with the primary endpoint (HR=1.10; p=0.04), as was systolic blood pressure (HR=1.02; p<0.001) and levels of glycosylated haemoglobin (HR=1.28; p=0.011). Patients with LVD had significantly worse outcome than those without (χ2=4.73; p=0.030). Conclusions: Subclinical LVD is common in asymptomatic patients with type 2 DM, is readily detectable by GLS imaging and is independently associated with adverse outcome. Trial registration number: Australian and New Zealand Clinical Trials Registry (ACTRN12612001178831).
dc.description.peerreviewedYes
dc.languageeng
dc.publisherBMJ
dc.relation.ispartofpagefrom1061
dc.relation.ispartofpageto1066
dc.relation.ispartofissue13
dc.relation.ispartofjournalHeart
dc.relation.ispartofvolume101
dc.subject.fieldofresearchCardiovascular medicine and haematology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3201
dc.subject.fieldofresearchcode3202
dc.titleSubclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationHolland, DJ; Marwick, TH; Haluska, BA; Leano, R; Hordern, MD; Hare, JL; Fang, ZY; Prins, JB; Stanton, T, Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus, Heart, 2015, 101 (13), pp. 1061-1066
dcterms.dateAccepted2015-04-13
dc.date.updated2022-01-25T09:56:19Z
gro.hasfulltextNo Full Text
gro.griffith.authorStanton, Tony
gro.griffith.authorHolland, David J.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record